Integra Lifesciences (IART) Announces Earnings Results, Hits Expectations

Share on StockTwits

Integra Lifesciences (NASDAQ:IART) issued its quarterly earnings data on Wednesday. The life sciences company reported $0.59 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.59, MarketWatch Earnings reports. The business had revenue of $365.85 million for the quarter, compared to the consensus estimate of $367.89 million. Integra Lifesciences had a return on equity of 17.43% and a net margin of 5.10%. The firm’s revenue was up 31.2% compared to the same quarter last year. During the same quarter last year, the business posted $0.45 EPS. Integra Lifesciences updated its FY 2018 guidance to $2.36-2.42 EPS and its FY18 guidance to $2.36-2.42 EPS.

Shares of NASDAQ IART traded down $8.54 during mid-day trading on Wednesday, hitting $53.78. The company had a trading volume of 27,916 shares, compared to its average volume of 468,548. The stock has a market capitalization of $5.20 billion, a price-to-earnings ratio of 27.85, a PEG ratio of 1.89 and a beta of 0.57. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.52 and a quick ratio of 2.27. Integra Lifesciences has a one year low of $45.96 and a one year high of $67.50.

Several analysts recently commented on the company. Morgan Stanley set a $68.00 price objective on Integra Lifesciences and gave the stock a “hold” rating in a research note on Thursday, October 11th. BidaskClub cut Integra Lifesciences from a “buy” rating to a “hold” rating in a report on Friday, July 27th. Cantor Fitzgerald reiterated a “hold” rating and set a $59.00 target price on shares of Integra Lifesciences in a report on Wednesday, July 25th. Zacks Investment Research upgraded Integra Lifesciences from a “sell” rating to a “hold” rating in a report on Tuesday, October 9th. Finally, Oppenheimer reiterated a “buy” rating and set a $74.00 target price on shares of Integra Lifesciences in a report on Wednesday, July 25th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating and five have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $62.15.

In other news, VP Glenn Coleman sold 8,916 shares of the firm’s stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $63.00, for a total value of $561,708.00. Following the completion of the transaction, the vice president now owns 16,795 shares in the company, valued at approximately $1,058,085. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Jeffrey Mosebrook sold 1,000 shares of the firm’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $62.42, for a total value of $62,420.00. Following the completion of the transaction, the insider now owns 3,085 shares of the company’s stock, valued at approximately $192,565.70. The disclosure for this sale can be found here. Insiders sold a total of 56,592 shares of company stock valued at $3,573,584 in the last 90 days. 5.10% of the stock is owned by corporate insiders.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

See Also: Return on Equity (ROE)

Earnings History for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply